StreetInsider.com News Articles

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events”

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: MOMTAZEE JAMES C

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796873.html

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: MOMTAZEE JAMES C

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796873.html

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Oren Ilan

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796874.html

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Oren Ilan

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796874.html

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Epperly Melissa B,

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796875.html

Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Epperly Melissa B,

Tue, 21 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260721/26796875.html

Arbutus sues Pfizer and BioNTech over LNP patents in 3 countries

Thu, 16 Jul 2026 07:30:48 -0400

Arbutus Biopharma Corporation (NASDAQ: ABUS) and its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV), filed three international patent infringement lawsuits against Pfizer Inc. and BioNTech SE over the use of lipid nanoparticle (LNP) technology in their mRNA COVID-19 vaccines.

The cases were filed in the Federal Court of Canada and at the Unified Patent Court (UPC), with the UPC actions covering 19 European countries including Germany, France, Italy, and Spain. The suits seek permanent injunctions and monetary damages, including recovery of profits from alleged infringement of specific Canadian and European patents.

The international actions expand on

Arbutus sues Pfizer and BioNTech over LNP patents in 3 countries

Thu, 16 Jul 2026 07:30:48 -0400

The international actions expand on

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech

Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to

Thu, 16 Jul 2026 07:30:00 -0400

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE)

Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Gline Matthew

Thu, 02 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26730069.html

Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Gline Matthew

Thu, 02 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26730069.html

Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Fitzgerald Meghan

Thu, 02 Jul 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260702/26730066.html